Core Insights - Defence Therapeutics Inc. is participating in CPHI Worldwide 2025, a major global pharmaceutical trade fair in Frankfurt, Germany from October 28-30, 2025 [1][2] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6] Event Participation - The company aims to engage with potential partners across the biopharma value chain and connect with the global pharmaceutical community to learn about the latest trends in pharmaceutical manufacturing [2] - Defence Therapeutics is hosting a Meet & Greet event on October 29, 2025, from 4:30-6:30 PM at the Kimpton Hotel in Frankfurt, providing an informal setting for networking and exploring partnership opportunities [3][4] CPHI Overview - CPHI is a leading global pharmaceutical trade show expected to attract over 62,000 visitors and around 2,400 exhibiting companies in 2025, featuring more than 180 international speakers [5]

Core Insights - Defence Therapeutics Inc. has appointed Dr. Mark Lambermon as Head of Quality and Operations, bringing over 20 years of experience in pharmaceutical R&D and biotech innovation [1][2] - Dr. Lambermon's expertise will be crucial for the company's regulatory readiness and operational excellence as it advances its drug delivery technologies [3] - The company has granted Dr. Lambermon 100,000 incentive stock options, exercisable at $0.80 per share for three years [4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells [5]

Group 1 - Defence Therapeutics Inc. has successfully closed a non-brokered private placement of debenture units, raising a total of $2,000,000 [1][5] - Each debenture unit consists of one $1,000 principal amount 8.0% convertible debenture and 1,666 common share purchase warrants [1][2] - The debentures have a maturity date of September 15, 2027, and are convertible into common shares at a price of $0.60 per share [2][3] Group 2 - The company paid a total of $160,000 in cash finder's fees and issued 266,667 finder's warrants, which are also exercisable at $0.75 per share [4] - The net proceeds from the offering will be used to advance the company's science programs and for general working capital [5] - All securities issued are subject to a statutory hold period of four months plus a day from their date of issue [5] Group 3 - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology [7]

Core Viewpoint - Defence Therapeutics Inc. is conducting a non-brokered private placement of debenture units to raise up to $1,200,000, aimed at enhancing its drug delivery technologies [1][2]. Financing Details - The offering consists of debenture units priced at $1,000 each, with a total gross proceeds target of $1,200,000 [1]. - Each unit includes one $1,000 principal amount of an 8.0% convertible debenture and 1,666 common share purchase warrants [1][2]. - The debentures will bear an interest rate of 8.0% per annum and will mature two years from the issue date [2]. - The principal amount of each debenture is convertible into common shares at a conversion price of $0.60 per share [2]. - Accrued interest can be paid annually in shares at the conversion price or in cash at the company's discretion [2]. Warrant Details - Each warrant allows the holder to acquire one common share at an exercise price of $0.75 for a period of two years from the issue date [3]. Regulatory and Compliance Information - All securities issued will be subject to a statutory hold period of four months and one day following the closing date [4]. - The completion of the offering is contingent upon receiving all necessary regulatory approvals [4]. - The company may pay a finder's fee to eligible arm's length finders in accordance with Canadian Securities Exchange policies [4]. Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6].

Core Insights - Defence Therapeutics Inc. is advancing its ADC and Radiopharma programs, focusing on collaborations and preclinical studies for cancer therapies using its Accum® technology [1][2][3] ADC Program - Defence's Accum®-based ADCs show improved intracellular delivery and cytotoxic activity in various preclinical cancer models compared to traditional ADCs [2] - The company is optimizing additional Accum®-based ADCs to enhance their value and attract potential licensing and co-development opportunities with Pharmaceuticals and Biotech companies [2] Radiopharmaceutical Program - The Radiopharma program is enhancing Accum® radiolabelling through studies conducted by Canadian Nuclear Laboratories, focusing on biodistribution, pharmacokinetics, and therapeutic potency [3] - The application of Accum® technology in the radiopharmaceuticals sector is expected to be transformative [3] Market Outlook - The global ADC market is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, with a CAGR of 9.23% from 2024 to 2034 [4] - The global radiopharmaceutical market is expected to reach USD 16.87 billion by 2033, growing at a CAGR of 9.9% during 2025-2033 [4] Future Developments - The company plans to announce key results and partnership details as they become available, while continuing its studies in Canada and expanding its presence to the US [5] - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology [6]